<p><span>Thailand Futures Exchange PCL (TFEX) today announced the awardees of six categories of TFEX Best Award 2021. KGI Securities (Thailand) pcl (KGI) obtained “Most Active House Award”; Country Group Securities pcl (CGS) was granted “Active Agent Award” in terms of transaction from investors; and Kasikorn Securities pcl (KS) was awarded “Popular Agent” in terms of investor base expansion. “Active Prop-Trading Award” was presented to Kiatnakin Phatra Securities pcl (KKPS); and “Market Maker Best Performance Award” was bestowed to Classic Ausiris Investment Advisory Securities Co., Ltd. (CAF). Furthermore, MTS Capital Co., Ltd. (MTSGF) won TFEX Best Award of Honor in recognition of the consistency in outstanding market maker performance during 2019-2021. </span></p>
Interest in eco-industrial zones gather capital pace vietnamnet.vn - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from vietnamnet.vn Daily Mail and Mail on Sunday newspapers.
Jab drives fuel domestic rise in petrol prices phnompenhpost.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from phnompenhpost.com Daily Mail and Mail on Sunday newspapers.
RNAi
Want a sneak peek into the Oligonucleotide Therapeutics market? Access the “Table of Content” of Oligonucleotide Therapeutics market report! https://www.persistencemarketresearch.com/toc/12787
Oligonucleotide Therapeutics Market: Region-wise Outlook
The presence of the main market leaders, market consolidation and commercialization of new molecules are all contributing towards the dominating position of North America in the oligonucleotides therapeutic market. Miragen Therapeutics, Inc. agreed to merge with Signal Genetics, Inc for an initial investment of USD 40 million. Through this merger both the companies expect to develop micro RNA-targeted oligonucleotide clinical products. New molecule application is also another strategy the market players are using to mark their presence in the oligonucleotide therapeutic market. Biogen recently received FDA approval for a new drug application for nusinersen. If approved, the antisense oligonucleotides molecule would be the f